8-K
false000106198300010619832024-05-082024-05-08

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 08, 2024

 

 

Cytokinetics, Incorporated

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

000-50633

94-3291317

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

350 Oyster Point Boulevard

 

South San Francisco, California

 

94080

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (650) 624-3000

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.001 par value

 

CYTK

 

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 2.02 Results of Operations and Financial Condition.

On May 8, 2024, Cytokinetics, Incorporated announced its financial results for the first quarter ended March 31, 2024. The full text of the press release issued in connection with this announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished under this Item 2.02 and under Exhibit 99.1 shall not be considered “filed” under the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Registrant expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

99.1 Press Release dated May 8, 2024

104 The cover page of this report has been formatted in Inline XBRL


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

CYTOKINETICS, INCORPORATED

 

 

 

 

Date:

May 8, 2024

By:

/s/ John O. Faurescu

 

 

 

John O. Faurescu, Esq., Associate General Counsel & Secretary

 


EX-99.1

 

https://cdn.kscope.io/ff3a657280240a5b0a77ba04b5090d2e-img114956760_0.jpg 

 

 

 

CYTOKINETICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS

 

Primary Results and Two Additional Analyses from SEQUOIA-HCM to be Presented in a Late-Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress

 

Initiated Enrollment in CEDAR-HCM, a Clinical Trial of Aficamten

in a Pediatric Population with Obstructive HCM

 

Announced Topline Data from the Phase 1 Study of CK-586;

Phase 2 Clinical Trial to Begin in Q4 2024

 

SOUTH SAN FRANCISCO, Calif., May 8, 2024 - Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the first quarter of 2024. Net loss for the first quarter was $135.6 million, or $1.33 per share, compared to net loss for the first quarter of 2023 of $131.3 million, or $1.38 per share. Cash, cash equivalents and investments totaled $634.3 million at March 31, 2024.

 

“In the first quarter, we advanced our muscle-biology portfolio anchored by the broad development program of aficamten. In parallel with our preparation of regulatory submissions in multiple geographies alongside executing on our go-to-market strategies, we also furthered ongoing clinical trials, FOREST-HCM, MAPLE-HCM and ACACIA-HCM, and started a fourth clinical trial of aficamten, CEDAR-HCM, a clinical trial in pediatric patients with obstructive HCM, another underserved cohort of patients with HCM,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “At the same time, we progressed CK-586 towards a Phase 2 clinical trial expected to begin later this year. We believe that our cohesive biology anchored in cardiac myosin positions the company well to fulfill our mission to deliver important medicines and increase shareholder value as will be further enabled by solid financials, access to diversified capital and executing on capital efficient Business and Corporate Development plans.”

 

Q1 and Recent Highlights

 

Cardiac Muscle Programs

 

aficamten (cardiac myosin inhibitor)

 

Announced three late-breaking clinical trial presentations relating to SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), at the

European Society of Cardiology Heart Failure 2024 Congress on May 13, 2024 in Lisbon, Portugal.

 

Participated in two meetings with the U.S. Food and Drug Administration (FDA) related to our New Drug Application (NDA) for aficamten, and continued activities supportive of our plan to submit the NDA in Q3 2024. Readied for a Type B meeting with FDA scheduled to occur in Q2 2024 to discuss key data that inform safety monitoring and risk minimization strategies for aficamten.

 

Continued preparing our Marketing Authorization Application (MAA) for aficamten, which we expect to submit to the European Medicines Agency (EMA) in Q4 2024.

 

Continued commercial readiness activities for aficamten including refining our market development campaign and product positioning as well as initiating the design and build of our patient support services program. Completed profiling HCM treatment programs, finalized our Payor Clinical Value Proposition and began development of our Payer Clinical Value Deck.

 

Presented additional data from FOREST-HCM (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM) in April at the American College of Cardiology 73ʳᵈ Annual Scientific Session demonstrating that treatment with aficamten for 48 weeks was associated with improvements in clinical efficacy endpoints, New York Heart Association (NYHA) Functional Class and cardiac biomarkers, structure and function, and was well-tolerated.

 

Initiated enrollment in CEDAR-HCM (Clinical Evaluation of Dosing with Aficamten to Reduce Obstruction in a Pediatric Population in HCM), a clinical trial of aficamten in a pediatric population with symptomatic obstructive HCM.

 

Continued enrolling patients in MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM), the Phase 3 clinical trial comparing aficamten as monotherapy to metoprolol as monotherapy in patients with symptomatic obstructive HCM. Enrollment is expected to be completed in Q3 2024.

 

Continued enrolling patients in ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM), the pivotal Phase 3 clinical trial of aficamten in patients with non-obstructive HCM. We expect to continue enrollment throughout 2024.

 

Published the following manuscripts:
“Exercise Capacity in Patients with Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM Baseline Characteristics and Study Design” in the Journal of the American College of Cardiology: Heart Failure.

 


“Efficacy and Safety of Aficamten in Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4” in the Journal of Cardiac Failure.

 

omecamtiv mecarbil (cardiac myosin activator)

 

Withdrew the Marketing Authorization Application (MAA) from the European Medicines Agency (EMA) for omecamtiv mecarbil based on feedback from the Committee for Medicinal Products for Human Use (CHMP) indicating that the Committee will not be able to conclude that the benefits outweigh the risks on the basis of the results from GALACTIC-HF alone.

 

CK-4021586 (CK-586, cardiac myosin inhibitor)

 

Announced topline data from the Phase 1 study of CK-586. The data support progression to a Phase 2 clinical trial in patients with heart failure with preserved ejection fraction (HFpEF) which we expect to start in Q4 2024.

 

CK-3828136 (CK-136, cardiac troponin activator)

 

Completed the Phase 1 study of CK-136 and began data analyses.

 

Pre-Clinical Development and Ongoing Research

 

Continued pre-clinical development and research activities directed to additional muscle biology focused programs. We expect to initiate clinical development with another muscle directed compound later this year.

 

Corporate

 

Announced the appointment of Sung Lee to serve as the Company’s Executive Vice President, Chief Financial Officer effective as of May 8, 2024.

 

Released 2023 Corporate Responsibility Report outlining the Company’s commitment and activities related to social and environmental responsibility, ethics and governance and patient and community engagement.

 

Awarded Cytokinetics Communications Fellowship Grants to patient advocacy organizations serving the HCM, heart failure and amyotrophic lateral sclerosis (ALS) communities to support increased capacity in communications, awareness building and community engagement.

 

Announced the launch of ENACT: Empower, Navigate, Activate for Clinical Trials, a joint initiative with The Mended Hearts, Inc. and WomenHeart: The National Coalition for Women with Heart Disease, to champion greater awareness and engagement in cardiovascular clinical

trials by reducing barriers, increasing support and empowering patients in groups historically underrepresented in clinical research.

 

Financials

 

Revenues for the first quarter 2024 were $0.8 million compared to $4.6 million for the corresponding period in 2023. The decrease in revenues was primarily due to milestone revenue of $2.5 million received from Ji Xing Pharmaceuticals for the start of ACACIA-HCM and higher collaboration revenues in 2023.

 

Research and development expenses for the first quarter 2024 increased to $81.6 million compared to $79.4 million for the same period in 2023, due to spending for our clinical development activities for our cardiac myosin inhibitor programs.

 

General and administrative expenses for the first quarter 2024 decreased to $45.5 million from $49.7 million for the same period in 2023 due to lower outside spending for pre-commercial launch activities.

 

Conference Call and Webcast Information

 

Members of Cytokinetics’ senior management team will review the company’s first quarter 2024 results on a conference call today at 4:30 PM Eastern Time. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics’ website at www.cytokinetics.com. The live audio of the conference call can also be accessed by telephone by registering in advance at the following link: Cytokinetics Q1 2024 Earnings Conference Call. Upon registration, participants will receive a dial-in number and a unique passcode to access the call. An archived replay of the webcast will be available via Cytokinetics’ website for twelve months.

 

About Cytokinetics

 

Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Cytokinetics is preparing for regulatory submissions for aficamten, its next-in-class cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in obstructive hypertrophic cardiomyopathy. Aficamten is also currently being evaluated in MAPLE-HCM, a Phase 3 clinical trial of aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM, ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM, CEDAR-HCM, a clinical trial of aficamten in a pediatric population with obstructive HCM, and FOREST-HCM, an open-label extension clinical study of aficamten in patients with HCM. . Cytokinetics is also developing omecamtiv mecarbil, a cardiac muscle activator, in patients with heart failure. Additionally, Cytokinetics is developing CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten for the potential treatment of HFpEF, and CK-136, a cardiac troponin activator


for the potential treatment HFrEF and other types of heart failure, such as right ventricular failure resulting from impaired cardiac contractility.

 

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

 

Forward-Looking Statements

 

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but not limited to, statements, express or implied, relating to our or our partners’ research and development and commercial readiness activities, including the initiation, conduct, design, enrollment, progress, continuation, completion, timing and results of any of our clinical trials, or more specifically, our ability to file a new drug application for aficamten in the United States in the third quarter of 2024 or a marketing authorisation application for aficamten in the European Union in the fourth quarter of 2024, our ability to complete enrollment of MAPLE-HCM in the third quarter of 2024 and to commence a Phase 2 study of CK-586, if ever, the timing of interactions with FDA or any other regulatory authorities in connection to any of our drug candidates and the outcomes of such interactions; statements relating to the potential patient population who could benefit from aficamten, omecamtiv mecarbil, aficamten, CK-586, CK-136 or any of our other drug candidates; statements relating to our ability to receive additional capital or other funding, including, but not limited to, our ability to meet any of the conditions relating to or to otherwise secure additional loan disbursements under any of our agreements with entities affiliated with Royalty Pharma or additional milestone payments from Ji Xing; statements relating to our operating expenses or cash utilization for the remainder of 2024, and statements relating to our cash balance at year-end 2024 or any other particular date or the amount of cash runway such cash balances represent at any particular time. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to Cytokinetics’ need for additional funding and such additional funding may not be available on acceptable terms, if at all; potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics’ drug candidates that could slow or prevent clinical development or product approval; patient enrollment for or conduct of clinical trials may be difficult or delayed; the FDA or foreign regulatory agencies may delay or limit Cytokinetics’ or its partners’ ability to conduct clinical trials; Cytokinetics may incur unanticipated research and development and other costs; standards of care may change, rendering Cytokinetics’ drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics’ drug candidates and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission, particularly under the caption “Risk Factors” in Cytokinetics’ Annual Report on Form 10-K for the year 2023. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak


only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

 

CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

 

###

 

Contact:

Cytokinetics

Diane Weiser

Senior Vice President, Corporate Affairs

(415) 290-7757

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cytokinetics, Incorporated


Condensed Consolidated Balance Sheets

(in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

March 31, 2024

 

December 31, 2023

 

 

(unaudited)

 

 

 ASSETS

 

 

 

 

 Current assets:

 

 

 

 

 Cash and short term investments

 

 $ 618,961

 

 $ 614,824

 Other current assets

 

                        19,743

 

                        13,227

 Total current assets

 

                      638,704

 

                      628,051

 Long-term investments

 

                        15,376

 

                        40,534

 Property and equipment, net

 

                        68,018

 

                        68,748

 Operating lease right-of-use assets

 

                        78,170

 

                        78,987

 Other assets

 

                           7,814

 

                           7,996

 Total assets

 

 $ 808,082

 

 $ 824,316

 LIABILITIES AND STOCKHOLDERS’ DEFICIT

 

 

 

 

 Current liabilities:

 

 

 

 

 Accounts payable and accrued liabilities

 

 $ 53,090

 

 $ 64,148

 Short-term operating lease liabilities

 

                        18,230

 

  17,891

 Current portion of long-term debt

 

                        11,520

 

  10,080

 Other current liabilities

 

                           6,015

 

                        10,559

 Total current liabilities

 

                        88,855

 

                      102,678

 Term loan, net

 

  56,822

 

                        58,384

 Convertible notes, net

 

                      549,790

 

                      548,989

 Liabilities related to revenue participation right purchase agreements, net

 

                      390,219

 

                      379,975

 Long-term operating lease liabilities

 

                      118,554

 

                      120,427

 Other non-current liabilities

 

                                  2

 

                              186

 Total liabilities

 

                   1,204,242

 

                   1,210,639

 Commitments and contingencies

 

 

 

 

 Stockholders’ deficit:

 

 

 

 

 Common stock

 

                              105

 

                              102

 Additional paid-in capital

 

                   1,852,155

 

                   1,725,823

 Accumulated other comprehensive loss

 

                            (539)

 

                              (10)

 Accumulated deficit

 

                 (2,247,881)

 

                 (2,112,238)

 Total stockholders’ deficit

 

                    (396,160)

 

                    (386,323)

 Total liabilities and stockholders’ deficit

 

 $ 808,082

 

 $ 824,316

 

 

 

 

 

 

 

 

 

Cytokinetics, Incorporated

Condensed Consolidated Statements of Operations


(in thousands except per share data)

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

March 31, 2024

 

March 31, 2023

Revenues:

 

 

 

 

Research and development revenues

 

 $ 835

 

 $ 2,113

Milestone revenues

 

  —

 

  2,500

Total revenues

 

                         835

 

                      4,613

Operating expenses:

 

 

 

 

Research and development

 

                    81,570

 

                    79,421

General and administrative

 

                    45,500

 

                    49,665

Total operating expenses

 

                 127,070

 

                 129,086

Operating loss

 

               (126,235)

 

               (124,473)

Interest expense

 

                    (7,103)

 

                    (6,961)

Non-cash interest expense on liabilities related to revenue participation right purchase agreements

 

  (10,218)

 

                    (6,280)

Interest and other income, net

 

                      7,913

 

                      6,425

Net loss

 

 $ (135,643)

 

 $ (131,289)

Net loss per share — basic and diluted

 

 $ (1.33)

 

 $ (1.38)

Weighted-average number of shares used in computing net loss per share — basic and diluted

 

                 101,924

 

                    95,164